Natural History Study for Patients With Nemaline Myopathy in the UK

Last updated: December 4, 2024
Sponsor: University of Oxford
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT06670378
NatHis-NM-MDUK
24/EE/0114
  • All Genders

Study Summary

The goal of this study is to to learn more about what assessments would be useful to measure for NM and what normally happens during the lives of people with NM to support future clinical trial development.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient and/or parent or legal guardian must be willing and have the ability toprovide written informed consent for participation in the study.

  • Male or Female

  • Any age

  • Diagnosis of NM which in most cases includes having a disease-causing variant/s inone of the known NM causative genes and a consistent clinical phenotype.

Exclusion

Exclusion Criteria:

  • Any confirmed chronic or acute condition or disease affecting any system(s), whichcould interfere with the results of the study and/or the compliance with the studyprocedures. This will be subject to the clinical judgement of the Chief Investigator (CI) and/or the Principal Investigator (PI).

  • Clinically significant medical finding on the physical examination other than NMthat, in the judgment of the Investigator, will make the patient unsuitable forparticipation in, and/or completion of the study procedures.

  • Participants of ongoing (interventional) clinical trials that assess the efficacy ofpotential treatments will be excluded as assessments need to be done on the basisthat represent the natural progression of NM.

  • Safety concerns. This includes anything that might put the participant and/or theirParent(s) or Guardian(s) at risk through participating in the study potentiallyincluding but not limited to: Safeguarding concerns, Social Issues and Healthissues.

Study Design

Total Participants: 45
Study Start date:
October 07, 2024
Estimated Completion Date:
August 31, 2029

Study Description

Current treatments for people living with nemaline myopathy are supportive only. Several potential therapies are in development which may be available in the next 5-10 years. The barrier to these becoming available is that there is little data available on the natural progression (natural history) of nemaline myopathy. This means that it would be difficult to do a clinical trial of a treatment because it is not known which assessments would be useful to measure or what normally happens during the lives of people with NM.This study aims to better define the natural history and disease specific outcome measures and biomarkers.

This study will comprehensively evaluate the natural clinical progression of the disease using medical data and examination findings, scales and questionnaires for the assessment of motor function, breathing, swallow function and Quality of life and fatigue. In addition it will collect data on continuous movement and gait analysis using real world data and wearable sensors (Syde and Maiju), blood samples for future genetic and proteomic analysis and respiratory analysis using ventilatory and thoraco-abdominal pattern for paediatric participants.

Connect with a study center

  • Department of Paediatric Neurology - Neuromuscular Service, Evelina Children's Hospital

    London,
    United Kingdom

    Site Not Available

  • Dubowitz Neuromuscular Centre, UCL Great Ormond Street Hospital

    London,
    United Kingdom

    Site Not Available

  • John Walton Muscular Dystrophy Research Centre, Newcastle University

    Newcastle,
    United Kingdom

    Active - Recruiting

  • MDUK Oxford Neuromuscular Centre, University of Oxford

    Oxford,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.